Payment overview · 2025
General Payments
$14.80
1 reported records · 1 companies
Healthcare provider profile · identity verified
Leonard Mark Wilk, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHITE CITY, OR · NPI 1326180688
Verified facts
What the public records show
CMS Open Payments records show Leonard Mark Wilk, MD received $14.80 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.80 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.80 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 615 | 148 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 539 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 529 | 141 |
| Omeprazole | Omeprazole | 419 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 79 |
| Losartan Potassium | Losartan Potassium | 268 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 266 | 90 |
| Gabapentin | Gabapentin | 239 | 59 |
| Lisinopril | Lisinopril | 232 | 66 |
| Potassium Chloride | Potassium Chloride | 217 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 215 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 183 | 25 |
| Trazodone Hcl | Trazodone Hcl | 174 | 40 |
| Furosemide | Furosemide | 171 | 45 |
| Simvastatin | Simvastatin | 171 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 46 |
| Sertraline Hcl | Sertraline Hcl | 170 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 44 |
| Pioglitazone Hcl | Pioglitazone Hcl | 159 | 32 |
| Meloxicam | Meloxicam | 157 | 38 |
| Ibuprofen | Ibuprofen | 136 | 33 |
| Metformin Hcl | Metformin Hcl | 136 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 136 | 18 |
| Alprazolam | Alprazolam | 130 | 23 |
| Pregabalin | Pregabalin | 129 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 33 |
| Baclofen | Baclofen | 126 | 36 |
| Buspirone Hcl | Buspirone Hcl | 125 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 28 |
| Lorazepam | Lorazepam | 104 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 40 |
| Azithromycin | Azithromycin | 100 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 18 |
| Carvedilol | Carvedilol | 83 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 21 |
| Atenolol | Atenolol | 79 | 15 |
| Alendronate Sodium | Alendronate Sodium | 73 | 12 |
| Eliquis | Apixaban | 73 | 19 |
| Xarelto | Rivaroxaban | 73 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 20 |
| Metformin Hcl Er | Metformin Hcl | 65 | 21 |
| Prednisone | Prednisone | 65 | 24 |
| Mirtazapine | Mirtazapine | 62 | 15 |
| Clonazepam | Clonazepam | 60 | 11 |
| Methylprednisolone | Methylprednisolone | 60 | 51 |
| Ozempic | Semaglutide | 60 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 32 |
| Montelukast Sodium | Montelukast Sodium | 57 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Lovastatin | Lovastatin | 56 | 13 |
| Celecoxib | Celecoxib | 53 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Allopurinol | Allopurinol | 49 | 11 |
| Spironolactone | Spironolactone | 49 | suppressed |
| Acyclovir | Acyclovir | 47 | 13 |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 13 |
| Nystatin | Nystatin | 45 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 12 |
| Tramadol Hcl | Tramadol Hcl | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Estradiol | Estradiol | 40 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Glipizide | Glipizide | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 11 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Colchicine | Colchicine | 27 | 11 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 12 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Constulose | Lactulose | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Etodolac | Etodolac | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.80 · 1 records | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error